ArticleBreast cancer (Tokyo, Japan)2026
Limited clinical value of routine PET/CT in early-stage breast cancer: a multicenter retrospective study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStaging of breast cancer at diagnosis is essential for prognosis and guiding treatment decisions. The role of ^18F-FDG positron emission tomography/computed tomography (PET/CT) in patients with asymptomatic early-stage breast cancer remains controversial because of the low prevalence of distant metastasis and risk of false-positive findings. MATERIALS AND
methodsThis is a retrospective multicenter cohort study across three tertiary centers in Lebanon. Adult patients with newly diagnosed stage I or IIA breast cancer who underwent PET/CT for initial staging between January 2019 and December 2024 were included. Patients receiving neoadjuvant therapy prior to imaging or with more advanced disease were excluded. Descriptive statistics were used to summarize outcomes, including rates of disease upstaging and false-positive findings.
resultsA total of 435 patients were included. Most tumors were invasive ductal carcinoma (88.0%) and hormone receptor-positive (ER 88.5%, PR 81.4%), with HER2 positivity in 17.7%. PET/CT resulted in stage upstaging in 23 patients (5.3%), 12 patients upstaged to stage IIA, 5 to stage IIB, and 6 to stage IV. However, histopathology confirmed distant metastases in only 3 patients (0.7%, 3/435). Overall, upstaging was pathologically confirmed in 11 patients, whereas it was not confirmed in 12 patients, with the discordant cases being predominantly attributable to false-positive nodal findings. PET/CT findings led to treatment modification in only 0.9% (4/435) of the cohort.
conclusionIn this cohort of asymptomatic patients with clinical stage I-IIA breast cancer, PET/CT rarely identifies additional metastatic disease and frequently results in false-positive findings. These results suggest a selective, risk-adapted use of PET/CT rather than routine staging in early-stage breast cancer, particularly in resource-constrained healthcare settings, and should be interpreted in the context of the study's retrospective design.
Indexed as
Identifiers
42867613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.